299 related articles for article (PubMed ID: 24045606)
1. Augmentation of aripiprazole for depressed patients with an inadequate response to antidepressant treatment: a 6-week prospective, open-label, multicenter study.
Jon DI; Kim DH; Seo HJ; Kwon YJ; Kim MD; Yang JC; Suh HS; Min KJ; Pae CU; Bahk WM
Clin Neuropharmacol; 2013; 36(5):157-61. PubMed ID: 24045606
[TBL] [Abstract][Full Text] [Related]
2. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.
Berman RM; Fava M; Thase ME; Trivedi MH; Swanink R; McQuade RD; Carson WH; Adson D; Taylor L; Hazel J; Marcus RN
CNS Spectr; 2009 Apr; 14(4):197-206. PubMed ID: 19407731
[TBL] [Abstract][Full Text] [Related]
3. The effectiveness and safety of adjunctive aripiprazole in Taiwanese patients with antidepressant-refractory major depressive disorder: a prospective, open-label trial.
Chen SJ; Hsiao YL; Shen TW; Chen ST
J Clin Psychopharmacol; 2012 Feb; 32(1):56-60. PubMed ID: 22198444
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
Marcus RN; McQuade RD; Carson WH; Hennicken D; Fava M; Simon JS; Trivedi MH; Thase ME; Berman RM
J Clin Psychopharmacol; 2008 Apr; 28(2):156-65. PubMed ID: 18344725
[TBL] [Abstract][Full Text] [Related]
5. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features.
Trivedi MH; Thase ME; Fava M; Nelson CJ; Yang H; Qi Y; Tran QV; Pikalov A; Carlson BX; Marcus RN; Berman RM
J Clin Psychiatry; 2008 Dec; 69(12):1928-36. PubMed ID: 19192475
[TBL] [Abstract][Full Text] [Related]
6. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.
Lin CH; Lin SH; Jang FL
J Clin Psychopharmacol; 2011 Oct; 31(5):563-8. PubMed ID: 21869699
[TBL] [Abstract][Full Text] [Related]
7. Aripiprazole augmentation for treatment of patients with chronic or recurrent major depressive disorder: a 12-week prospective open-label multicentre study.
Pae CU; Jeon HJ; Lee BC; Seo HJ; Kim SG; Park EJ; Kim W; Kwak KP; Han C; Cho SJ; Hahn SW; Jon DI; Choi JH; Jun TY
Int Clin Psychopharmacol; 2013 Nov; 28(6):322-9. PubMed ID: 23873293
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants.
Thase ME; Youakim JM; Skuban A; Hobart M; Augustine C; Zhang P; McQuade RD; Carson WH; Nyilas M; Sanchez R; Eriksson H
J Clin Psychiatry; 2015 Sep; 76(9):1224-31. PubMed ID: 26301701
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.
Berman RM; Marcus RN; Swanink R; McQuade RD; Carson WH; Corey-Lisle PK; Khan A
J Clin Psychiatry; 2007 Jun; 68(6):843-53. PubMed ID: 17592907
[TBL] [Abstract][Full Text] [Related]
10. Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning.
Fava M; Okame T; Matsushima Y; Perry P; Weiller E; Baker RA
Int J Neuropsychopharmacol; 2017 Jan; 20(1):22-30. PubMed ID: 27784751
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the efficacy between paroxetine and sertraline augmented with aripiprazole in patients with refractory major depressive disorder.
Yoshimura R; Kishi T; Hori H; Ikenouchi-Sugita A; Katsuki A; Umene-Nakano W; Iwata N; Nakamura J
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Dec; 39(2):355-7. PubMed ID: 22813840
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis.
Steffens DC; Nelson JC; Eudicone JM; Andersson C; Yang H; Tran QV; Forbes RA; Carlson BX; Berman RM
Int J Geriatr Psychiatry; 2011 Jun; 26(6):564-72. PubMed ID: 20827794
[TBL] [Abstract][Full Text] [Related]
13. Global benefit-risk analysis of adjunctive aripiprazole in the treatment of patients with major depressive disorder.
Wisniewski SR; Chen CC; Kim E; Kan HJ; Guo Z; Carlson BX; Tran QV; Pikalov A
Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):965-72. PubMed ID: 19662630
[TBL] [Abstract][Full Text] [Related]
14. Response and remission rates with adjunctive aripiprazole in patients with major depressive disorder who exhibit minimal or no improvement on antidepressant monotherapy.
Casey DE; Laubmeier KK; Eudicone JM; Marcus R; Berman RM; Rahman Z; Sheehan J
Int J Clin Pract; 2014 Nov; 68(11):1301-8. PubMed ID: 25196314
[TBL] [Abstract][Full Text] [Related]
15. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study.
Thase ME; Youakim JM; Skuban A; Hobart M; Zhang P; McQuade RD; Nyilas M; Carson WH; Sanchez R; Eriksson H
J Clin Psychiatry; 2015 Sep; 76(9):1232-40. PubMed ID: 26301771
[TBL] [Abstract][Full Text] [Related]
16. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder.
Simon JS; Nemeroff CB
J Clin Psychiatry; 2005 Oct; 66(10):1216-20. PubMed ID: 16259533
[TBL] [Abstract][Full Text] [Related]
17. Analysis of suicidality in pooled data from 2 double-blind, placebo-controlled aripiprazole adjunctive therapy trials in major depressive disorder.
Weisler RH; Khan A; Trivedi MH; Yang H; Eudicone JM; Pikalov A; Tran QV; Berman RM; Carlson BX
J Clin Psychiatry; 2011 Apr; 72(4):548-55. PubMed ID: 20816039
[TBL] [Abstract][Full Text] [Related]
18. A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study).
Fava M; Mischoulon D; Iosifescu D; Witte J; Pencina M; Flynn M; Harper L; Levy M; Rickels K; Pollack M
Psychother Psychosom; 2012; 81(2):87-97. PubMed ID: 22286203
[TBL] [Abstract][Full Text] [Related]
19. Beneficial acute antidepressant effects of aripiprazole as an adjunctive treatment or monotherapy in bipolar patients unresponsive to mood stabilizers: results from a 16-week open-label trial.
Mazza M; Squillacioti MR; Pecora RD; Janiri L; Bria P
Expert Opin Pharmacother; 2008 Dec; 9(18):3145-9. PubMed ID: 19040335
[TBL] [Abstract][Full Text] [Related]
20. Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: a randomized, double-blind, placebo-controlled study (ADMIRE study).
Kamijima K; Higuchi T; Ishigooka J; Ohmori T; Ozaki N; Kanba S; Kinoshita T; Koyama T;
J Affect Disord; 2013 Dec; 151(3):899-905. PubMed ID: 24074484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
